Agenus downgraded by H.C. Wainwright with a new price target
$AGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
H.C. Wainwright downgraded Agenus from Buy to Neutral and set a new price target of $9.00
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/4/2025 | $25.00 | Neutral → Buy | H.C. Wainwright |
7/19/2024 | $35.00 → $8.00 | Outperform → Neutral | Robert W. Baird |
7/18/2024 | Outperform → Mkt Perform | William Blair | |
7/18/2024 | $9.00 | Buy → Neutral | H.C. Wainwright |
6/6/2023 | $8.00 | Outperform | Robert W. Baird |
6/6/2023 | $60.00 → $80.00 | Outperform | Robert W. Baird |
2/28/2023 | $8.00 | Buy | H.C. Wainwright |
9/28/2022 | $5.00 | Outperform | SMBC Nikko |